Welcome to our dedicated page for Rocket Pharmaceu SEC filings (Ticker: RCKT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Rocket Pharmaceuticals, Inc. (RCKT) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed, late-stage biotechnology company, Rocket uses SEC reports to communicate material information about its gene therapy pipeline, financial condition, governance and significant corporate events.
Investors can use this page to locate current reports on Form 8-K, which Rocket files to describe events such as financial results, strategic corporate reorganization and pipeline prioritization, clinical trial developments and regulatory milestones. Recent 8-K filings referenced in available information include announcements of quarterly financial results, FDA acceptance of the resubmitted Biologics License Application (BLA) for KRESLADI in severe leukocyte adhesion deficiency-I (LAD-I), lifting of the clinical hold on the pivotal Phase 2 trial of RP-A501 for Danon disease, and leadership or board changes.
In addition to 8-Ks, users can access Rocket’s periodic reports on Forms 10-K and 10-Q, which provide more detailed discussions of its AAV and lentiviral gene therapy programs, risk factors and financial statements. These filings help explain how Rocket is prioritizing its AAV cardiovascular platform—covering Danon disease, PKP2-arrhythmogenic cardiomyopathy and BAG3-associated dilated cardiomyopathy—while advancing regulatory activities for KRESLADI and pausing additional internal investment in certain other programs.
Stock Titan enhances these filings with AI-powered summaries that highlight key points from lengthy documents, such as clinical and regulatory updates, restructuring plans, and changes in executive leadership. Real-time EDGAR updates allow users to see new Rocket filings as they are posted, while Form 4 insider transaction data and proxy materials can be reviewed to understand equity awards, inducement grants and governance practices. This page serves as a focused entry point for analyzing how Rocket’s SEC disclosures relate to the development and potential commercialization of its rare disease gene therapy portfolio.
Form 144 for Rocket Pharmaceuticals, Inc. (RCKT) reports a proposed sale of 7,043 common shares through Fidelity Brokerage Services with an approximate aggregate market value of $21,260.70, and an approximate sale date of 08/14/2025 on NASDAQ. These shares were acquired on 08/12/2025 by restricted stock vesting from the issuer as compensation. The filing lists total shares outstanding of 107,903,871.
The notice also discloses two prior sales by the same person during the past three months: 655 shares on 05/16/2025 for $4,275.51 and 357 shares on 05/20/2025 for $2,301.22. The filer affirms they are not aware of any undisclosed material adverse information about the issuer.
Rocket Pharmaceuticals, Inc. (RCKT) Form 144 notifies a proposed sale of 12,109 common shares (aggregate market value $36,553.44) to be sold on or about 08/14/2025 on NASDAQ. The shares were acquired by vesting of restricted stock from the issuer on 08/12/2025 and were paid as compensation. The filing also discloses two recent sales by Martin Wilson of 946 and 587 shares on 05/16/2025 and 05/20/2025, generating gross proceeds of $6,175.02 and $3,783.80 respectively. The document shows the total shares outstanding as 107,903,871. Several standard filer contact and signature fields appear blank in the provided content.
Form 144 notice for proposed sale of common stock tied to restricted stock vesting. The filing shows 11,161 shares of Common stock to be sold through Fidelity Brokerage Services LLC on 08/14/2025 with an aggregate market value of $33,691.71. The shares were acquired on 08/12/2025 as Restricted Stock Vesting and paid as Compensation. The filer who sold shares in the past three months is identified as Jonathan D. Schwartz, with two prior sales on 05/16/2025 (1,582 shares for $10,326.51) and 05/20/2025 (801 shares for $5,163.25). The filing lists the issuer-related fields but does not provide the issuer name or address in the supplied content.
The filing also reports 107,903,871 shares outstanding, which makes the proposed sale approximately 0.0103% of outstanding shares based on provided figures.
Rocket Pharmaceuticals disclosure shows that Maverick-affiliated entities and Lee S. Ainslie beneficially hold 8,363,813 shares of common stock, equal to 7.8% of the company based on 107,737,919 shares outstanding. The reported holdings arise from multiple funds and accounts: Maverick Fund USA, Ltd. (1,686,548 shares); Maverick Fund II, Ltd. (1,727,675); Maverick Long Enhanced Fund, Ltd. (1,930,078); Maverick HP, L.P. (1,726,954); Maverick Long Fund, Ltd. (958,547); and separately managed accounts (334,011).
Maverick is identified as the investment adviser with investment discretion over these client accounts, Maverick Capital Management is the general partner, and Lee S. Ainslie III is the manager. The filing reports no sole voting or dispositive power and shared voting and dispositive power over all 8,363,813 shares, indicating a significant institutional stake without unilateral control.
Item 2.02: On August 7, 2025 Rocket Pharmaceuticals, Inc. announced preliminary financial information for the quarter ended June 30, 2025 via a press release furnished as Exhibit 99.1. The filing states the exhibit is furnished, not filed under Item 2.02 and therefore not subject to Section 18 liability.
Item 5.02: Effective December 31, 2025, Dr. Kinnari Patel will leave the Company to join RTW Investments LP as a venture partner. As of August 8, 2025 she no longer serves as President, Head of Research and Development and will assist in transitioning her duties to other executives. Exhibits include the press release (99.1) and Inline XBRL cover page (104). The report is signed by Martin Wilson on August 7, 2025.